MAA (Molecular Affinity Analysis) is a platform for in situ detection and quantification of therapeutic binding sites on patient tumor tissue. It enables precise assessment of target accessibility, binding site density, and spatial distribution, providing valuable insights for biomarker validation, patient stratification, and therapy optimization. MAA is compatible with a wide range of therapeutics, including small molecules, monoclonal antibodies, bispecific antibodies, ADCs, radioligands, and CAR-T cell targets, making it a versatile approach for advancing precision oncology.
MAA offers a wide range of applications across the drug development lifecycle. Here are just a few examples of how MAA can support different stages:
We invite you to connect with us to explore how our Molecular Affinity Analysis (MAA) platform can address your research and clinical objectives. Whether your focus is on enhancing clinical trial strategies, or advancing therapeutic profiling, our team is ready to provide tailored support and expert guidance.
Contact us to discuss your specific needs, request detailed information, or learn more about how MAA technology can contribute to your success in drug development and precision oncology.